Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables ...
Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...
Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...
The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the ...
In people with familial high cholesterol and extraordinarily high levels of cholesterol, combination therapy with two or ...
Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s ...
Repatha® (evolocumab) can be used to help adults at increased risk for major adverse cardiovascular events lower their LDL-C ...
* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback